Advertisement

Journal of Nuclear Cardiology

, Volume 1, Supplement 2, pp S86–S96 | Cite as

Merits and limitations of radionuclide approaches to viability and future developments

  • Heinrich R. Schelbert
Article

Abstract

Radionuclide imaging approaches have proved useful for the noninvasive identification of a potentially reversible impairment of contractile function in human myocardium. Foremost among these approaches are (1) the thallium 201 uptake, redistribution, and reinjection technique and (2) the evaluation of blood flow and metabolism with positron emission tomography (PET). Both general approaches appear equally accurate in predicting the postrevascularization outcome of regional contractile function. In patients with severely depressed left ventricular function who are likely to benefit most from viability assessments, the available evidence suggests that the metabolic approach with PET outperforms the more conventional approach with201Tl. Several investigations have suggested that PET can identify those patients with a low probability of long-term survival, as well as patients in whom revascularization will reduce mortality rates, improve global left ventricular function, and relieve related symptoms of congestive heart failure. Moreover, several new radionuclide techniques are currently emerging. They probe key points of viable myocardium, such as residual oxidative metabolism, fatty acid uptake and oxidation, membrane function, and cellular homeostasis. Although initial observations have been encouraging, further validation and especially testing in those patients in whom viability assessment is clinically critical will be required. These new approaches may also offer new insights into the mechanisms of reversible contractile dysfunction in the human myocardium.

Key Words

myocardial viability positron emission tomography metabolism thallium 201 fluorine 18-labeled deoxyglucose 

References

  1. 1.
    Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988;12:1456–63.PubMedGoogle Scholar
  2. 2.
    Dilsizian V, Rocco T, Freedman N, Leon M, Bonow R. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141–6.PubMedGoogle Scholar
  3. 3.
    Mori T, Minamiji K, Kurogane H, Ogawa K, Yoshida Y. Rest-injected thallium-201 imaging for assessing viability of severe asynergic regions. J Nucl Med 1991;32:1718–24.PubMedGoogle Scholar
  4. 4.
    Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW. Quantitative planar rest-redistribution201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993;87:1630–41.PubMedGoogle Scholar
  5. 5.
    Marshall RC, Tillisch JH, Phelps ME, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766–78.PubMedGoogle Scholar
  6. 6.
    Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8.PubMedGoogle Scholar
  7. 7.
    Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991;32:673–8.PubMedGoogle Scholar
  8. 8.
    Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am J Cardiol 1990;66:394–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Carrel J, Jenni R, Haubold-Reuter S, Von Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992;6:479–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Gropler R, Siegel B, Sampathkumaran K, Perez J, Bergmann S, Geltman E. Comparison of positron emission tomography using C-11 acetate with F-18 fluorodeoxyglucose in predicting myocardial viability J Am Coll Cardiol 1991;17:121A.Google Scholar
  13. 13.
    Marwick T, MacIntyre W, Lafont A, Nemec J, Salcedo E. Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation 1992;85:1347–53.PubMedGoogle Scholar
  14. 14.
    Brunken R, Mody F, Hawkins R, Nienaber C, Phelps M, Schelbert H. Metabolic imaging with positron emission tomography detects viable tissue in myocardial segments with persistent defects on twenty-four hour tomographic thallium-201 scintigraphy. Circulation 1992;86:1357–69.PubMedGoogle Scholar
  15. 15.
    Louie H, Laks H, Milgalter E, et al. Ischemic cardiomyopathy: criteria for coronary revascularization and cardiac transplantation. Circulation 1991;84:III290–5.PubMedGoogle Scholar
  16. 16.
    Eitzman D, Al-Aouar Z, Kanter H, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559–65.PubMedGoogle Scholar
  17. 17.
    Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging. J Am Coll Cardiol 1993;22:1621–7.PubMedGoogle Scholar
  18. 18.
    Besozzi MC, Brown MD, Hubner KF, et al. Retrospective post therapy evaluation of cardiac function in 208 coronary artery disease patients evaluated by positron emission tomography [Abstract]. J Nucl Med 1992;33:885.Google Scholar
  19. 19.
    Di Carli M, Davidson M, Little R, et al. The value of PET for predicting prognosis in patients with coronary artery disease and left ventricular dysfunction: the value of myocardial perfusion and metabolism imaging by positron emission tomography. Am J Cardiol (in press).Google Scholar
  20. 20.
    Opie LH. Myocardial ischemia: metabolic pathways and implications of increased glycolysis. Cardiol Drugs Ther 1990;4:777–90.CrossRefGoogle Scholar
  21. 21.
    Iida H, Rhodes C, de Silva R, et al. Myocardial tissue fraction: correction for partial volume effects and measure of tissue viability. J Nucl Med 1991;32:2169–75.PubMedGoogle Scholar
  22. 22.
    Yamamoto Y, De Silva R, Rhodes C, et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using15O-water and dynamic positron emission tomography. Circulation 1992;86:167–78.PubMedGoogle Scholar
  23. 23.
    de Silva R, Yamamoto Y, Rhodes C, et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992;86:1738–42.PubMedGoogle Scholar
  24. 24.
    Gould L, Yoshida K, Hess M, Haynie M, Mullani N, Smalling R. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med 1991;32:1–9.PubMedGoogle Scholar
  25. 25.
    Buxton DB, Nienaber CA, Luxen A, et al. Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1–11C] acetate and dynamic positron emission tomography. Circulation 1989;79:134–42.PubMedGoogle Scholar
  26. 26.
    Brown MA, Myears DW, Bergmann SR. Noninvasive assessment of canine myocardial oxidative metabolism with 11C-acetate and positron emission tomography. J Am Coll Cardiol 1988;12:1054–63.PubMedGoogle Scholar
  27. 27.
    Henes CG, Bergmann SR, Walsh MN, Sobel BE, Geltman EM. Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. J Nucl Med 1989;30:1489–99.PubMedGoogle Scholar
  28. 28.
    Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR. Regional myocardial oxygen consumption determined noninvasively in humans with [1–11C] acetate and dynamic positron tomography. Circulation 1989;80:863–72.PubMedGoogle Scholar
  29. 29.
    Gropler R, Siegel B, Sampathkumaran K, et al. Dependence of recovery of contractile function on maintenance and oxidative metabolism after myocardial infarction. J Am Coll Cardiol 1992;19:989–97.PubMedGoogle Scholar
  30. 30.
    Gropler R, Geltman E, Sampathkumaran K, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992;20:569–77.PubMedGoogle Scholar
  31. 31.
    Feigl E, Neat G, Huang A. Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol 1990;22:375–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Czernin J, Porenta G, Brunken R, et al. Regional blood flow, oxidative metabolism and glucose utilization in patients with acute myocardial infarction. Circulation 1993;88:884–95.PubMedGoogle Scholar
  33. 33.
    Schwaiger M, Schelbert HR, Ellison D, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol 1985;6:336–47.PubMedCrossRefGoogle Scholar
  34. 34.
    Schön HR, Schelbert HR, Najafi A, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography, I: kinetics of C-11 palmitic acid in normal myocardium. Am Heart J 1982;103:532–47.PubMedCrossRefGoogle Scholar
  35. 35.
    Rosamond TL, Abendschein DR, Sobel BE, Bergmann SR, Fox KAA. Metabolic fate of radiolabeled palmitate in ischemic canine myocardium: implications for positron emission tomography. J Nucl Med 1987;28:1322–9.PubMedGoogle Scholar
  36. 36.
    Fox KAA, Abendschein DR, Ambos HD, Sobel BE, Bergmann SR. Efflux of metabolized and nonmetabolized fatty acid from canine myocardium: implications for quantifying myocardial metabolism tomographically. Circ Res 1985;57:232–43.PubMedGoogle Scholar
  37. 37.
    Schelbert HR, Henze E, Schön HR, et al. C-11 palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography, III: in vivo demonstration of the effects of substrate availability on myocardial metabolism. Am Heart J 1983;105:492–504.PubMedCrossRefGoogle Scholar
  38. 38.
    Schön HR, Schelbert HR, Najafi A, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography, II: kinetics of C-11 palmitic acid in acutely ischemic myocardium. Am Heart J 1982;103:548–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Schelbert HR, Henze E, Schön HR, et al. C-11 palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography, IV: in vivo demonstration of impaired fatty acid oxidation in acute myocardial ischemia. Am Heart J 1983;106:736–50.PubMedCrossRefGoogle Scholar
  40. 40.
    Sochor H, Czernin J, Schelbert H. Metabolic imaging with single-photon emitting tracers. In: Marcus MY, Schelbert HR, Wolf GL, eds. Cardiac imaging. Philadelphia: WB Saunders, 1991:1085–96.Google Scholar
  41. 41.
    Tamaki N, Kawamoti M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992;33:659–67.PubMedGoogle Scholar
  42. 42.
    Kuikka J, Mustonen J, Uusitupa M, et al. Demonstration of disturbed free fatty acid metabolism of myocardium in patients with non-insulin-dependent diabetes mellitus as measured with iodine-123-heptadecanoic acid. Eur J Nucl Med 1991;18:475–81.PubMedGoogle Scholar
  43. 43.
    Murray G, Schad N, Ladd W, et al. Metabolic cardiac imaging in severe coronary disease: assessment of viability with iodine-123-iodophenylpentadecanoic acid and multicrystal gamma camera, and correlation with biopsy. J Nucl Med 1992;33:1269–77.PubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 1994

Authors and Affiliations

  • Heinrich R. Schelbert
    • 1
    • 2
  1. 1.From the Division of Nuclear Medicine, Department of PharmacologySchool of MedicineUSA
  2. 2.the Laboratory of Nuclear Medicine, Laboratory of Biomedical and Environmental SciencesUniversity of CaliforniaLos Angeles

Personalised recommendations